Technical Analysis for RGEN - Repligen Corporation

Grade Last Price % Change Price Change
D 138.90 8.10% 10.41
RGEN closed up 8.1 percent on Wednesday, November 20, 2024, on 1.39 times normal volume.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Multiple of Ten Bullish Other 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 8.10%
Outside Day Range Expansion 8.10%
Gapped Down Weakness 8.10%
Lower Bollinger Band Touch Weakness 8.10%
Oversold Stochastic Weakness 8.10%
Jack-in-the-Box Bearish Bearish Swing Setup 12.55%

   Recent Intraday Alerts

Alert Time
Rose Above 20 DMA about 18 hours ago
Rose Above 10 DMA about 18 hours ago
20 DMA Resistance about 18 hours ago
Up 1 ATR about 20 hours ago
Up 5% about 20 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Repligen Corporation Description

Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed ‘plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Natural Sciences Monoclonal Antibody 3 D Orphan Drug Consumable Products Imaging Agent Chromatography Bioprocessing Cell Culture Bioprocess Drug Manufacturing Growth Factor Products

Is RGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 211.13
52 Week Low 113.5
Average Volume 645,805
200-Day Moving Average 156.34
50-Day Moving Average 140.21
20-Day Moving Average 138.22
10-Day Moving Average 138.11
Average True Range 7.62
RSI (14) 50.00
ADX 16.57
+DI 30.05
-DI 25.91
Chandelier Exit (Long, 3 ATRs) 131.63
Chandelier Exit (Short, 3 ATRs) 144.37
Upper Bollinger Bands 152.23
Lower Bollinger Band 124.22
Percent B (%b) 0.52
BandWidth 20.27
MACD Line -1.99
MACD Signal Line -0.96
MACD Histogram -1.0311
Fundamentals Value
Market Cap 7.76 Billion
Num Shares 55.8 Million
EPS 2.03
Price-to-Earnings (P/E) Ratio 68.42
Price-to-Sales 17.09
Price-to-Book 5.76
PEG Ratio 2.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 154.91
Resistance 3 (R3) 153.23 146.21 152.24
Resistance 2 (R2) 146.21 142.14 147.05 151.35
Resistance 1 (R1) 142.56 139.62 144.39 144.24 150.46
Pivot Point 135.54 135.54 136.46 136.38 135.54
Support 1 (S1) 131.89 131.47 133.72 133.57 127.34
Support 2 (S2) 124.87 128.95 125.71 126.45
Support 3 (S3) 121.22 124.87 125.56
Support 4 (S4) 122.90